Caroline Clairmont

Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of<i>Salmonella typhimurium</i>

Caroline Clairmont, K. C. Lee, Jeremy A. Pike et al. · The Journal of Infectious Diseases · 2000 · 350 citations · Full text

Life Sciences, Genetics, Molecular Biology +9

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

John Nemunaitis, Casey Cunningham, Neil Senzer et al. · Cancer Gene Therapy · 2003 · 338 citations

Medicine, Biotechnology, Oncology +9

Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion

Scott Wadler, Della Makower, Caroline Clairmont et al. · Journal of Clinical Oncology · 2004 · 146 citations

Medicine, Pharmacokinetics, Pharmacology +17

Translocation of ATP into the lumen of rough endoplasmic reticulum-derived vesicles and its binding to luminal proteins including BiP (GRP 78) and GRP 94.

Caroline Clairmont, Antonio De Maio, C B Hirschberg · Journal of Biological Chemistry · 1992 · 135 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +11

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

John R. Murren, Manuel Modiano, Caroline Clairmont et al. · PubMed · 2003 · 108 citations

Pharmacy, Pharmacokinetics, Pharmacology +17